Clinical and Metabonomics Study on the Treatment of Heart Failure After Myocardial Infarction With Modified Wenxin Decoction

• Status: Not yet recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: All

Summary

To elucidate the efficacy and safety of weixin decoction in the treatment of heart failure after myocardial infarction.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jun Li

Criteria

Inclusion Criteria:

• 18-75 years old；

• A history of acute myocardial infarction；

• Cardiac function Ⅱ - Ⅲ level；

• LVEF 50% or less;

• Nt-probnp level ≥ 450 pg/ mL；

• All men and women can sign the informed consent form.

Exclusion Criteria:

• Coronary artery bypass grafting was performed within 12 weeks；

• Undergo or possibly undergo cardiac resynchronization therapy;

• Primary valvular disease, left ventricular outflow tract obstruction, myocarditis, aneurysm, uncontrolled severe arrhythmia, cardiogenic shock, unstable angina pectoris, or acute myocardial infarction;

• Having a serious primary liver, kidney or blood system disease or having a serious mental illness or a systemic disease that is out of control;

• Serum creatinine > 194.5 mol/L or serum potassium > 5.5mmol /L;

• The level of alanine aminotransferase or alkaline phosphatase is 1.5 times of the normal upper limit of >;

• Abnormal blood pressure control, systolic blood pressure exceeding 180mmHg or diastolic blood pressure exceeding 110mmHg;

• Pregnancy or lactation; Known or suspected allergy to research drugs; To receive another investigational drug within 30 days of randomization or to be unwilling or unable to provide written consent.